Publications by authors named "Sofia Barreto Pittol"
Article Synopsis
- Type 2 diabetes (T2D) requires personalized treatment, and the study focuses on OW semaglutide, a medication approved for T2D management in real-world settings.
- The SURE Spain study included adults with T2D and aimed to evaluate the impact of semaglutide on HbA levels, body weight, and patient-reported outcomes over approximately 30 weeks.
- Results showed significant improvements, with an average HbA reduction of -1.3% and a weight loss of -5.7 kg, without new safety issues reported.
